Vergelijkende Pathologie van Aterosclerose bij Niet-menselijke Primaten

Een Historisch-Kritisch Overzicht van Progressie, Stabilisatie, Regressie en Plaque-Lipiden-Dynamiek (1950–1995)

Samenvatting

Het paradigma van aderverkalking in het midden van de twintigste eeuw overgaat van het beschouwen van de aandoening als een onvermijdelijke, progressieve gevolg van veroudering naar het begrijpen ervan als een dynamische, lipide-gedreven ontstekingsziekte waarin aanzienlijke regressie en stabilisatie biologisch mogelijk zijn onder bepaalde experimentele omstandigheden. Veel van het fundamentele bewijs voor deze verschuiving werd vastgesteld via niet-menselijke primatenmodellen die werden ontwikkeld tussen 1950 en de late jaren 1980. Vergeleken met veel vaak gebruikte knaagdier- en konijnenmodellen, bezitten geselecteerde niet-menselijke primaten lipoproteïne stofwisseling, apolipoproteïne B (ApoB) biologie en de coronaire arteriële anatomie die belangrijke kenmerken van humane atherosclerose beter benaderen. Dit historisch onderbouwde wetenschappelijke overzicht onderzoekt de progressie, stabilisatie en regressie van door voeding geïnduceerde atherosclerose bij verschillende primatensoorten, waaronder rhesusapen, langstaartmakaken, groene meerkatten, bavianen en doodshoofdaapjes.

Deze historische onderzoeken tonen aan dat geselecteerde niet-menselijke primaten complexe, mensachtige kransslagaderen ontwikkelen plaques met in de hoofdrol vezelige kappen, lipiderijke necrotische kernen, hermodellering van de extracellulaire matrix en verkalking. Spontaan myocardinfarct werd ook gemeld, hoewel veel minder vaak. Bovendien leveren seriële en postmortale analyses experimenteel bewijs dat aanzienlijke en aanhoudende omkering of hypercholesterolemie, bereikt door ingrijpende dieetveranderingen en, in sommige experimenten, aanvullende lipidennederlagende interventies, kunnen induceren plaqueregressie. In al deze onderzoeken werden regressie en stabilisatie gekenmerkt door uitputting van intracellulaire en extracellulaire plaque-cholesterylesterpools en door vermindering van lipidenrijke cellulaire en necrotische componenten; onderzoeken waarin de vasculaire functie direct werd beoordeeld, toonden bovendien herstel aan van endotheliale vasomotorische reacties. Dicht fibrotische en macrocalcificerende matrixcomponenten persisteren niettemin vaak, waardoor volledige anatomische normalisatie wordt beperkt. Door de dieet-, kinetische en methodologische parameters van deze historische studies te evalueren, biedt dit rapport een translationele brug naar moderne humane studies, waarbij zowel de translationele relevantie als de biologische grenzen van plaqueregressietherapie worden geschetst.

Historische evolutie en tijdlijn

De systematische studie van atherosclerose bij niet-menselijke primaten is geëvolueerd via distincte experimentele fasen, waarbij de vooruitgang in de analytische biochemie, histopathologie en beeldvormingstechnologieën werd gevolgd. De onderstaande tabel schetst de mijlpalen van dit onderzoek en beschrijft hoe onderzoeken vorderden van vroege observatie van vasculaire lipidedeposito's tot functionele, hoge-resolutie-evaluaties van plaquebiologie.

Punt	Experimentele Focus & Methodologische Vooruitgang	Belangrijke baanbrekende onderzoekscentra	Baanbrekende wetenschappelijke bijdragen
jaren 1950	Inductie van hypercholesterolemie en vasculaire lipidenkleuring bij Nieuwe Wereld-primaten; verkenning van voedingstekorten.	Harvard School of Public Health; Bowman Gray School of Medicine.	Onder de vroege experimentele inducties van hypercholesterolemie bij apen uit de Nieuwe Wereld; karakterisering van de vasculaire gevoeligheid van Cebus en rhesus.
jaren 1960	Focus op kransslagaders slagader pathologie en natuurlijke historie; vroege rapporten over spontaan myocardinfarct bij hyperlipidemische apen.	Northwestern University; Oregon Regional Primate Research Center.	Taylor et al. documenteren een fatale, door voeding veroorzaakt myocardinfarct bij een rhesusmakaak [1]. Maruffo & Portman bestuderen vroege coronaire veranderingen bij doodshoofdaapjes [2].
Jaren 1970	Morfometrisch bewijs van gevorderde coronaire regressie; gedetailleerde in kaart brenging van plaque-lipidenfasen en matrixveranderingen.	University of Iowa; University of Chicago; LSU Medical Center.	Armstrong et al. leveren vroeg morfometrisch bewijs van gevorderde coronaire atheroom regressie bij rhesusapen3]. Vesselinovitch & Wissler evalueren vetarme diëten in combinatie met een farmacologisch lipidenverlagend middel (W-1372) [4].
jaren 1980	Langdurige, meerjarige kinetische studies van regressie; fysisch-chemische analyses van lipidenfasetransities; epidemiologische modellering van HDL.	Bowman Gray School of Medicine; Boston University; Southwest Foundation for Biomedical Research.	Clarkson et al. vergelijken de lange-termijnregressie bij totale plasmacolesterolspiegels rond 200 versus 300 mg/dl [5]. Small et al. karakteriseren tijdelijke plaquekristallisatie bij een regressie van 6 maanden6].
jaren negentig	Integratie van histomorfometrie met kwantitatieve angiografie, endotheelreactiviteit en compensatoire vasculaire remodellering.	Bowman Gray School of Medicine; LSU Medical Center.	Williams et al. melden een ongeveer verdubbelde kransslagader- en lumen doorsneden, in overeenstemming met gunstige externe remodeling, samen met verbeterde vasomotore functie [7]. LSU-team voltooi een meerjarige studie naar rhesusp plaques [8].

Primate modellen: Soortspecifieke pathobiologie en metabole profielen

De selectie van een niet-menselijke primatensoort bij atheroscleroseonderzoek wordt geleid door genetische, metabolische en anatomische overwegingen. Het kiezen van het juiste model is van cruciaal belang, aangezien soortverschillen in lipoproteïnetransport en arteriële gevoeligheid direct van invloed zijn op de vertaling van experimentele resultaten naar de menselijke klinische praktijk.

Rhesusaapjes (Macaca mulatta)

Rhesusaapen zijn historisch gezien het meest gebruikte primatenmodel voor atheroscleroseonderzoek. Onder invloed van een atherogeen dieet kunnen vatbare rhesusaapen verschuiven van relatief HDL-dominante baseline lipoproteïneprofielen naar een duidelijke verrijking van ApoB-bevattende lipoproteïnen, wat een plasmaprofiel oplevert dat sterke overeenkomsten vertoont met belangrijke kenmerken van humane hyperlipoproteïnemie. Rhesusaapen reageren sterk op voedingscholesterol en verzadigd vet. Ze ontwikkelen betrouwbaar gevorderde, concentrische en excentrische coronairplaques die zich ontwikkelen tot necrotische kern vorming, celafbraak, intraplaque-bloeding, en verkalking. Spontaneous myocardinfarcten zijn gedocumenteerd, hoewel ze zeldzaam bleven in langetermijnstudies met rhesusaapjes, waardoor deze diersoort een vooraanstaand model is voor klinisch kransslagaderziekte.

Langstaartmakaken (Macaca fascicularis)

Kakabeuken zijn uiterst gevoelig voor dieet cholesterol, waardoor ze een uitstekend model zijn voor snelle laesie inductie. Ze zijn gevoelig voor het ontwikkelen van gevorderde coronaire arteriële laesies met een hoog aandeel bindweefsel, waaronder collageen, elastine, en glycosaminoglycanen, evenals dichte verkalking. Cynomolgus-apen vertonen ook een mate van psychosociale stressreactiviteit. Psychosociale stress en sociale status zijn experimenteel in verband gebracht met verschillen in kransslagaders atherogenese bij deze soort, in het bijzonder gerapporteerd bij dominante mannetjes en bij sociaal ondergeschikte vrouwtjes, waarbij activatie van het sympatische zenuwstelsel en hypercortisolemie worden voorgesteld als neuroocriene mechanismen die bijdragen naast circulerende lipideneconcentraties. Dit maakt ze een waardevol model voor het onderzoeken van de relatie tussen psychosociale stress en vaatziekten.

Afrikaanse groene apen (Chlorocebus aethiops)

Afrikaanse groene apen (vervets) bezitten een lipoproteïnestofwisseling die zeer gevoelig is voor de specifieke vetzuursamenstelling van het dieet. Bij voeding met enkelvoudig onverzadigde versus verzadigde of meervoudig onverzadigde vetten, ze vertonen duidelijke variaties in LDL grootte en dichtheid relevant voor de lipidenresponsen in de menselijke voeding. Hun coronaire laesies ontwikkelen zich langzamer dan die van makaken, maar vertonen belangrijke morfologische overeenkomsten met menselijke plaques, waaronder de distributie van de laesies en de aanwezigheid van beide gladde spiercellen en macrofaag schuimcellen, hoewel soortspecifieke verschillen in cellulaire samenstelling en lipidenmetabolisme blijven bestaan.

Bavianen (Papio hamadryas/sp.)

Bavianen zijn grote, genetisch heterogene Oude Wereld-primaten die veel worden gebruikt om de genetische en omgevingsdeterminanten van cardiovasculair risico te bestuderen. Ze ontwikkelen op natuurlijke wijze vroegtijdige vetstrepen en fibreuze plaques bij voorspelbare arteriële takken, waaronder de iliaca-bifurcatie en de abdominale aorta. Hun groei, ontwikkeling en veroudering volgen een algemeen patroon van Oude Wereld-primaten, en ze vertonen mensachtige variaties in lipoproteïneresponses, bloeddruk, en vaatcompliance onder dieetuitdaging. Ze zijn echter relatief resistent tegen het ontwikkelen van ernstige, occlusieve kransslagadervernauwing of terminale ischemische gebeurtenissen binnen de standaard experimentele tijdsbestekken, wat hun nut voor geavanceerde regressiestudies beperkt.

Doodshoofdaapjes (Saimiri sciureus)

Als kleine Nieuwe Wereld-primaten bieden doodshoofdaapjes een compact model voor atheroscleroseonderzoek. Ze ontwikkelen op natuurlijke wijze aortale en coronaire laesies en reageren sterk op kortetermijnmanipulaties van dieetvetten. Terugkeer naar een cholesteroolarm dieet bij doodshoofdaapjes kan de hoeveelheid lipiden en schuimcellen in laesies verminderen en de the progressie van vroege laesies stoppen; de mate van kwantitatief aangetoonde anatomische regressie in de vroege literatuur over doodshoofdaapjes is minder zeker. Hun kleine vatdiameter en algehele fysieke afmetingen compliceren echter seriële angiografie, intravasculaire beeldvorming en regionale hemodynamische stromingsmetingen.

Vergelijkende voordelen van primatenmodellen ten opzichte van niet-primatenmodellen

Niet-menselijke primaten bieden verschillende fysiologische en structurele voordelen boven lagere zoogdiermodellen voor vraagstukken over humane kransslagaderziekte, hoewel geen enkele soort optimaal is voor elk doel en andere modellen (konijnen, varkens en genetisch gemodificeerde muizen) te verkiezen kunnen zijn voor specifieke mechanistische, interventionele of beeldvormende vraagstukken:

• Lipoproteïneverdeling & CETP Activiteit Gewone laboratoriummuizen en -ratten vervoeren een groot deel van hun circulerende cholesterol in HDL-deeltjes en missen aanzienlijke plasma cholesterylester overdragen eiwit (CETP-)activiteit. Deze kenmerken maken spontane, mensachtige, op ApoB-dominante hyperlipidemie ongebruikelijk bij deze soorten en vereisen vaak genetische of dieetmatige manipulatie om humane atherosclerose te modelleren. Veel niet-menselijke primatensoorten bezitten CETP-activiteit en ontwikkelen, wanneer ze worden uitgedaagd met dieetcholesterol en verzadigd vet, een aanzienlijke stijging van ApoB-bevattende lipoproteïnen en een lipoproteïnedistributie die lijkt op humane hypercholesterolemie. De lipoproteïnedistributie bij de uitgangswaarde varieert desondanks aanzienlijk naar soort, kolonie, dieet, geslacht en individuele responsiviteit, en verschillende primaten zijn relatief HDL-dominant vóór het voeren van cholesterol.
• Arteriële anatomie en hemodynamica: Niet-menselijke primaten bezitten een meerlagige, dikke kransslagader intima met een goed gedefinieerde interne elastische lamina en adventitia vasa vasorum, die verschillende belangrijke kenmerken van de menselijke coronaire vasculaire architectuur delen. Konijnen daarentegen reageren uiterst gevoelig op dieetcholesterol en accumuleren gemakkelijk met lipiden beladen macrofaagschuimcellen (de “Anitschkow-cel” respons); onder langdurige of aangepaste protocollen kunnen ze ook meer gevorderde fibreuze, necrotische en verkalkte laesies ontwikkelen. Hun extreme gevoeligheid voor dieetcholesterol, afwijkend lipoproteïnemetabolisme en frequente concentratie van de ziekte in de aorta in plaats van in spontane mensachtige coronaire gebeurtenissen beperken niettemin de directe translatie ten opzichte van geselecteerde primatenmodellen.
• Ontstekings- en Trombotische Cascaden: Primaten vertonen een sterk geconserveerde ontstekingscascade en maken gebruik van nauw verwante homologe celadhesiemoleculen (VCAM-1, ICAM-1), monocyten chemoattractantia (MCP-1) en scavenger-receptoren (CD36, SR-A1) om macrofaagrecruitment en -activatie binnen de plaque te stimuleren. Bovendien komen primate stollingssystemen, plaatjesreactiviteit en fibrinolytische cascades nauw overeen met de menselijke biologie in vergelijking met die van veel knaagdier- of vogelmodellen, hoewel spontane mensachtige plaqueruptuur, intraplaque-bloeding en luminale trombose zelfs bij primaten ongebruikelijke experimentele eindpunten blijven.

Relevantierangschikking van Grote Onderzoeksprogramma's

De onderstaande tabel toont een door de auteur gegenereerde relevantierangschikking (niet de uitvoer van een systematische literatuurstudie) van tien informatieve onderzoeksprogramma's met niet-menselijke primaten op basis van hun relevantie voor humane kransslagaderatherosclerose. De set omvat zowel regressiestudies als vergelijkende progressiestudies (met name de programma's van Rudel en McGill), die dienovereenkomstig zijn gelabeld. Programma's zijn gerangschikt naar soortgeschiktheid, de complexiteit en locatie van de geïnduceerde laesies (kransslagaders versus aorta), de duur van de experimentele voedingsperioden, de aanwezigheid van een gecontroleerde regressiefase, de meting van plasmalipoproteïnesubfracties en het detailniveau van de postmortem kransslagaderhistopathologie.

Ranglijst	Onderzoeksprogramma & Hoofdonderzoekers	Primaire soort	Complexe coronaire laesie	Studie-opzet & Kinetische Duur	Wetenschappelijke onderbouwing voor rangschikking
1	Iowa Coronary Regression Program (Armstrong, Warner & Connor)	Rhesusaap	Ernstig; ernstige diffuse kransslagaderlijke stenose, necrose, met lipiden gevulde plaques.	17 maanden introductie; 40 maanden regressie.	Fundamentele studie: Tot de vroegste rigoureuze morfometrische aantoonbaarheid van aanzienlijke anatomische regressie en lipidedepletie in de kransslagaders van een primatenmodel, dat een aanzienlijke vermindering van door dieet geïnduceerde coronaire atheromatose en verbeterde lumenafmetingen laat zien.
2	LSU-langeretermijnregressieprogramma (Strong, Bhattacharyya, Eggen, Newman, et al.)	Rhesusaap	Hoge; gestructureerde, mature fibromusculaire coronairplaques met lipidenkernen.	5,4 jaar inductie; 1,9 of 3,7 jaar regressie.	Temporele nauwkeurigheid: Behoort tot de langstdurende primateninductiestudies, waarbij vergelijkenderwijs rijpe en structureel complexe plaques worden geproduceerd die chronische humane laesies beter benaderen dan kortere inductiemodellen; toonde aan dat regressie van gevorderde laesies pas aantoonbaar wordt na jaren van aanhoudende lipidenverlagend.
3	Bowman Gray Primate Center-serie V (Clarkson, Bond, Bullock, McLaughlin, Sawyer)	Rhesusaap	Hoog; concentrische en excentrische coronairlaesies met necrose en calcificatie.	38 maanden inductie; 24 of 48 maanden regressie.	Doelkalibratie: Vergeleken regressie bij twee vooraf bepaalde plasmacolesterolniveaus; in dit rhesusmodel, aanhoudend plasma totaal cholesterol waarden rond 200 mg/dl waren geassocieerd met een consistentere kransslagaderregressie dan niveaus rond 300 mg/dl.
4	Bowman Gray Vrouwelijke Regressie Programma (Williams, Anthony, Honoré, Register, Clarkson, et al.)	Langstaartmakaak	Hoog; complex verkalkte plaques, verlies van endotheelafhankelijke vasomotorische reactiviteit.	24 maanden inductie; 30 maanden regressie.	Functionele integratie: Toonde aan dat lipidenverlaging de kransslagaderlumen ongeveer kan verdubbelen — consistent met gunstige uitwaartse remodellering — en de vaatvatfunctie verbetert, zelfs wanneer de plaque-grootte niet afneemt.
5	Boston / Bowman Gray Lipidenfaseprogramma (Small, Bond, Waugh, Prack, Sawyer)	Langstaartmakaak	Matig-hoog; epicardiale coronairplaque's, prominente cellulaire necrose.	18–30 maanden inductie; 6 of 12 maanden regressie.	Biofysisch inzicht: De fysisch chemie van lipiden in de plaque gekarakteriseerd; een voorbijgaande kristallijne vrij-cholesterolfase beschreven tijdens vroege snelle lipidenmobilisatie.
6	Chicago Reversal Program (Vesselinovitch, Wissler, Hughes, Borensztajn)	Rhesusaap	Matig tot hoog; ernstige aorta- en proximale coronaire plaque.	18 maanden inductie; 18 maanden regressie.	Gecombineerde interventie: Het toevoegen van het farmacologische lipidenverlagende middel W-1372 aan een vetarm regressiedieet was geassocieerd met een sterkere lipidenlaging en een grotere verbetering van de laesies dan het dieet alleen, met opruiming van schuimcellen en een gerapporteerde verbetering van het endotheeloppervlak.
7	Oregon Alfalfa Saponine Programma (Malinow, McLaughlin, Naito, McNulty, et al.)	Langstaartmakaak	Gematigd; uitgebreide coronaire schuimcelinfiltratie en vroege plaques.	6 maanden introductie; 18 maanden regressie.	Mechanistische diversificatie: Alfalfa-bevattende diëten werden geassocieerd met verlaagd plasmacholesterol en een verminderde laesiebeasting tijdens aanhoudende cholesterolvoeding; verminderde darm- sterol absorptie gemedieerd door saponinen werd voorgesteld als één mechanisme.
8	Wake Forest / Bowman Gray Vetzurenprogramma (Rudel, Parks, Sawyer)	Groene apenvogel	Matig-hoog; proximale coronaire laques rijk aan cholesterylesters.	5 jaar continue inductie (vergelijkende vetstudie).	Lipoproteïnebiologie: Stelde de aanname ter discussie dat voedingsvetten equivalent zijn; in dit cholesterolbevattende experimentele model werd het dieet met enkelvoudig onverzadigd vet geassocieerd met grotere, met cholesteryloleaat verrijkte LDL-deeltjes en werd coronaire atherosclerose niet in dezelfde mate verminderd als werd gezien bij het dieet met meervoudig onverzadigd vet.
9	Southwest Foundation Baboon Program (McGill, McMahan, Kruski, Mott)	Papio sp.	Low-Moderate; aortic and iliac bifurcational fatty streaks and early plaques.	26 months continuous atherogenic induction.	Controlled Lipoprotein Association: Showed a positive association of LDL and a negative association of HDL with plaque coverage under controlled conditions, providing controlled experimental support for associations also observed in humans.
10	Oregon New World Program (Maruffo & Portman)	Saimiri sciureus	Low-Moderate; early proximal coronary foam cell lesions.	3–12 months induction; 3–12 months control-diet follow-up.	Early Validation: One of the first programs to examine the fate of early coronary foam-cell lesions in a New World primate after dietary lipid normalization.

Individual Structured Evidence Profiles

The following structured profiles present the scientific data and pathological findings for each of the ranked research programs. Bibliographic details have been verified against the primary literature; quantitative values drawn from the original reports are presented as published.

Rank 1: Iowa Coronary Regression Program (Armstrong, Warner, & Connor, 1970)

Full citation	[3] Armstrong M. L., Warner E. D., Connor W. E. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970 Jul;27(1):59–67.
Year	1970
Primate species	Macaca mulatta (Rhesus macaque)
Number of animals	40
Sex and approximate age	Adult males, age unknown (wild-caught)
Duration of atherogenic feeding	17 months
Duration of regression phase	40 months
Experimental diet composition	Semipurified diet containing 41% of total calories from fat, 19% from protein, and 40% from koolhydraat.
Control / regression diet	Low-fat diet (4% calories as fat) OR corn-oil diet (40% calories as corn oil). Both were cholesterol-free.
Dietary cholesterol content	1.2% by weight during induction; 0% (cholesterol-free) during regression.
Total-fat percentage	41% (induction), 40% (corn-oil regression), 4% (low-fat regression).
Saturated-fat percentage	High saturated fat during induction (egg-yolk fat); low saturated fat during corn-oil regression.
Achieved lipids & lipoproteins	Induction: 711 ± 31 mg/dl (TC). Low-fat regression: 141 ± 7 mg/dl. Corn-oil regression: 140 ± 8 mg/dl. Historical electrophoretic analysis showed reversal of the beta-lipoprotein-dominant pattern.
Arterial territories examined	Extramural coronary arteries (LAD, LCx, RCA), aorta, and peripheral arteries.
Plaque-assessment method	Histomorphometry of microscope-projected sections traced on paper, cut, and weighed.
Evidence of coronary disease	Severe, diffuse coronary atheromatosis with marked luminal narrowing across five evaluation sites.
Evidence of plaque progression	High-fat, high-cholesterol feeding caused extensive progression of lesions in 17 months.
Evidence of true regression	Regression animals had an average coronary lumen cross-sectional area more than 80% greater than that of animals with baseline atherosclerosis, with no significant difference between the low-fat and corn-oil regression diets. This is a measurement of lumen dimensions rather than a direct measurement of plaquevolume.
Evidence of plaquestabilisatie	Remaining lesions were flatter and lipid-depleted, with proportionally greater dense fibrous tissue.
Calcification / thrombosis / death	No fatal infarctions reported in this specific cohort; minimal baseline calcification observed.
Main conclusions	In this rhesus model, uncomplicated coronary atheromas regressed substantially when plasma lipids were normalized by either low-fat or corn-oil regression diets.
Major limitations	Small sample sizes, lack of baseline coronary biopsies in surviving animals, and lack of modern lipoprotein assays.
Relevance to human disease	Very High; demonstrated the biological feasibility of substantial improvement in coronary arterial geometry following diet-induced normalization of plasma lipids in a primate model.

Rank 2: LSU Long-Term Regression Program (Strong, Bhattacharyya, Eggen, Newman, et al., 1994)

Full citation	[8] Strong J. P., Bhattacharyya A. K., Eggen D. A., et al. Long-term induction and regression of diet-induced atherosclerotic lesions in rhesus monkeys. Two separately published companion papers, both listed under reference [8]: Part I, Arterioscler Thromb. 1994;14(6):958–965; Part II, Arterioscler Thromb. 1994;14(12):2007–2016.
Year	1994
Primate species	Macaca mulatta (Rhesus macaque)
Number of animals	45
Sex and approximate age	Young adult males, 3–6 years of age at baseline
Duration of atherogenic feeding	5.4 years
Duration of regression phase	1.9 years (Group R4) or 3.7 years (Group R5)
Experimental diet composition	High-saturated-fat, high-cholesterol diet: 38% of calories from fat, 15% from protein, and 47% from carbohydrate.
Control / regression diet	Saturated-fat diet without cholesterol (38% fat, 15% protein, 47% carbohydrate; cholesterol deleted).
Dietary cholesterol content	0.35 mg/kcal during induction; 0.02 mg/kcal during regression.
Total-fat percentage	38.0% of total calories
Saturated-fat percentage	26.2% of total calories (polyunsaturated/saturated ratio of 0.35).
Achieved lipids & lipoproteins	Serum cholesterol rose from a pre-induction mean near 150 mg/dl to a mean of about 430 mg/dl during induction, and returned toward baseline (approximately 150 mg/dl) during regression.
Arterial territories examined	Aorta, coronary arteries (LAD, LCx, RCA), common carotid, external carotid, and peripheral arteries.
Plaque-assessment method	Visual estimation of aortic surface lesion area, chemical lipid extraction, and histomorphometry of perfusion-fixed sections.
Evidence of coronary disease	Concentric and eccentric plaques with measurable coronary luminal reduction at baseline.
Evidence of plaque progression	5.4 years of induction produced extensive progression of raised lesions and elevated plaque cholesteryl esters.
Evidence of true regression	Statistically demonstrable decrease in intimal thickness and plaque area became apparent after approximately 3.7 years of regression (Group R5), but not at 1.9 years.
Evidence of plaque stabilization	Substantial reduction in plaque esterified cholesterol, with remaining lesions composed of dense collagenous scars.
Calcification / thrombosis / death	Advanced calcification in the abdominal aorta and proximal coronaries, which remained largely unchanged during regression.
Main conclusions	In this model, advanced diet-induced coronary lesions showed morphometrically demonstrable regression only after prolonged lipid lowering, with clearer regression at 3.7 years than at 1.9 years.
Major limitations	Prolonged study length resulted in animal attrition; small sample size in late regression cohorts.
Relevance to human disease	Extremely High; its unusually long induction and regression periods produced comparatively mature lesions, making it particularly informative for considering the slower regression kinetics of chronic human disease.

Rank 3: Bowman Gray Primate Center Series V (Clarkson, Bond, Bullock, McLaughlin, Sawyer, 1984)

Full citation	[5] Clarkson T. B., Bond M. G., Bullock B. C., McLaughlin K. J., Sawyer J. K. A study of atherosclerosis regression in Macaca mulatta. V. Changes in abdominal aorta, carotid, and coronary arteries. Exp Mol Pathol. 1984 Aug;41(1):96–118.
Year	1984
Primate species	Macaca mulatta (Rhesus macaque)
Number of animals	48
Sex and approximate age	Young adult males, age approximately 4–5 years at baseline
Duration of atherogenic feeding	38 months
Duration of regression phase	24 or 48 months
Experimental diet composition	Semipurified atherogenic diet (approximately 40–44% of calories from fat, primarily lard).
Control / regression diet	Titrated semipurified diets where cholesterol content was adjusted individually to maintain specific plasma total-cholesterol ceilings.
Dietary cholesterol content	Approximately 0.35–1.0 mg/Cal during induction; dynamically titrated during regression.
Total-fat percentage	Approximately 40–44% (induction); lower fat during regression titrations.
Saturated-fat percentage	High saturated fat during induction (lard/beef tallow/butter).
Achieved lipids & lipoproteins	Induction: 450 ± 25 mg/dl (TC). Regression Group 1: 316 ± 10 mg/dl. Regression Group 2: 204 ± 4 mg/dl.
Arterial territories examined	Abdominal aorta, thoracic aorta, coronary arteries (LAD, LCx, RCA), and common carotid bifurcations.
Plaque-assessment method	Perfusion-fixed morphometry, detailed histological grading, and biochemical analysis of tissue cholesteryl esters.
Evidence of coronary disease	Concentric fibro-lipid coronary plaques with prominent necrotic cores and medial thinning.
Evidence of plaque progression	38 months of induction produced severe coronary plaques. Progression continued in a substantial fraction of the 300 mg/dl cohort.
Evidence of true regression	Coronary plaque regressed significantly after 48 months at 200 mg/dl, but not after 24 months, showing time-dependence.
Evidence of plaque stabilization	Monkeys at 200 mg/dl showed near-complete resolution of necrotic zones and a relative increase in dense collagen matrix.
Calcification / thrombosis / death	High baseline calcification. Calcification frequency was substantially lower in the 200 mg/dl group than in the 300 mg/dl group.
Main conclusions	In this model, regression of advanced coronary plaques was observed when plasma total cholesterol was held near 200 mg/dl for several years, but not at levels near 300 mg/dl.
Major limitations	High individual genetic variability (hyper- vs. hypo-responders) confounded findings in the 300 mg/dl regression cohort.
Relevance to human disease	High; indicates that the achieved lipid level and the duration of exposure are both important determinants of regression.

Rank 4: Bowman Gray Female Regression Program (Williams, Anthony, Honoré, Register, Clarkson, et al., 1995)

Full citation	[7] Williams J. K., Anthony M. S., Honoré E. K., Herrington D. M., Morgan T. M., Register T. C., Clarkson T. B. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 1995 Jul;15(7):827–836.
Year	1995
Primate species	Macaca fascicularis (Cynomolgus macaque)
Number of animals	88 (baseline necropsy n=20; diet-only n=25; +conjugated equine oestrogenen n=22; +estrogens/medroxyprogesterone n=21)
Sex and approximate age	Surgically postmenopausal (bilaterally ovariectomized) adult females
Duration of atherogenic feeding	24 months
Duration of regression / treatment phase	30 months
Experimental diet composition	Semipurified atherogenic diet (approximately 44% of calories from fat, 16% protein, 40% carbohydrate).
Control / regression diet	Low-fat, low-cholesterol diet enriched with safflower oil.
Dietary cholesterol content	High during induction; markedly reduced during the regression/treatment phase.
Achieved lipids & lipoproteins	Induction: approximately 470 mg/dl (TC). Regression: decreased to a mean near 140 mg/dl in the diet-only and hormone-added groups.
Arterial territories examined	Extramural coronary arteries (LAD, LCx, RCA) and abdominal aorta.
Plaque-assessment method	Perfusion-fixed coronary morphometry and vascular-ring vasomotor reactivity.
Evidence of coronary disease	Advanced, calcified epicardial coronary plaques causing baseline luminal narrowing.
Evidence of plaque progression	24 months of induction produced severe concentric and eccentric coronary lesions.
Evidence of true regression	Cross-sectional plaque size did not change significantly compared with the baseline necropsy cohort.
Evidence of plaque stabilization	Coronary artery and lumen cross-sectional area approximately doubled compared with the baseline group, consistent with favorable (outward) remodeling; endothelium-dependent vasomotor dilation to acetylcholine was improved.
Calcification / thrombosis / death	Advanced calcification remained largely unchanged; its persistence limits anatomical normalization and does not by itself indicate healing.
Main conclusions	Clinically relevant benefit is not restricted to plaque shrinkage; lipid lowering was associated with enlargement of coronary artery and lumen cross-sectional area and improved endothelial reactivity, consistent with favorable remodeling.
Major limitations	Emphasis on postmenopausal hormone interactions; the advanced lesions did not show direct volumetric shrinkage.
Relevance to human disease	Extremely High; provides a mechanistically relevant example of how lipid lowering can improve arterial geometry and endotheelfunctie despite little change in plaque cross-sectional area, a pattern relevant to human clinical observations.

Rank 5: Boston / Bowman Gray Lipid Phase Program (Small, Bond, Waugh, Prack, Sawyer, 1984)

Full citation	[6] Small D. M., Bond M. G., Waugh D., Prack M., Sawyer J. K. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984 Jun;73(6):1590–1605.
Year	1984
Primate species	Macaca fascicularis (Cynomolgus macaque)
Number of animals	54
Sex and approximate age	Adult males, age approximately 5–6 years at baseline
Duration of atherogenic feeding	Up to 30 months (progression animals evaluated at 6, 12, 18, 24, and 30 months)
Duration of regression phase	6 or 12 months (after 18 months of induction)
Experimental diet composition	Semipurified diet containing dextrin, salts, vitamin mixture, and butterfat/lard.
Control / regression diet	Standard commercial non-cholesterol-containing monkey chow.
Dietary cholesterol content	0.36 mg/Cal during induction; cholesterol-free during regression.
Total-fat percentage	Approximately 40% of calories as fat during induction; low fat during chow regression.
Saturated-fat percentage	High (butterfat and lard) during induction.
Achieved lipids & lipoproteins	Induction: 520 ± 30 mg/dl (TC). 6-month regression: 148 ± 12 mg/dl. 12-month regression: 140 ± 10 mg/dl.
Arterial territories examined	Thoracic aorta, abdominal aorta, common carotid, and coronary arteries.
Plaque-assessment method	Perfusion histomorphometry, hot-stage polarizing microscopy, and chemical lipid extraction.
Evidence of coronary disease	Advanced, occlusive fibro-lipid epicardial coronary plaques with large necrotic cores.
Evidence of plaque progression	Plaque cholesteryl esters increased, forming foam-cell-rich lesions with high-melting-point intracellular lipid droplets.
Evidence of true regression	Return to chow shifted plaque lipid composition toward normal; by 12 months, arterial cholesterol, cholesterol crystals, and necrosis had decreased and the intima appeared improved but scarred.
Evidence of plaque stabilization	After 12 months of regression, cell debris and necrotic core size were significantly reduced, and collagen content increased.
Calcification / thrombosis / death	During early regression, a transient increase in free cholesterol monohydrate crystals was observed, interpreted as cholesteryl-ester hydrolysis temporarily exceeding cholesterol efflux.
Main conclusions	Plaque regression involves complex, time-dependent chemical changes; rapid lipid lowering can induce a transient crystalline phase during lipid mobilization.
Major limitations	Confined to a single species with rapid lipid-loading responses.
Relevance to human disease	High; elucidated the physical chemistry of plaque lipid mobilization, providing a physicochemical explanation for why structural improvement may lag behind biochemical lipid depletion.

Rank 6: Chicago Reversal Program (Vesselinovitch, Wissler, Hughes, Borensztajn, 1976)

Full citation	[4] Vesselinovitch D., Wissler R. W., Hughes R., Borensztajn J. Reversal of advanced atherosclerosis in Rhesus monkeys. Part 1. Light-microscopic studies. Atherosclerosis. 1976;23(2):155–176. Cited jointly as [4] with the companion ultrastructural report: Weber G., Fabbrini P., Resi L., Jones R., Vesselinovitch D., Wissler R. W. Atherosclerosis. 1977;26(4):535–547.
Year	1976
Primate species	Macaca mulatta (Rhesus macaque)
Number of animals	54
Sex and approximate age	Young adult males, 3–4 years of age at baseline
Duration of atherogenic feeding	18 months
Duration of regression phase	18 months
Experimental diet composition	Semipurified diet with 25% by weight of a 1:1 coconut-oil / butterfat mixture, plus casein and cornstarch.
Control / regression diet	Low-fat, low-cholesterol diet with or without the investigational lipid-lowering compound W-1372 (an experimental agent, not a clinically approved drug).
Dietary cholesterol content	2.0% by weight during induction; cholesterol-free during regression.
Total-fat percentage	High saturated fat during induction; less than 5% during regression.
Saturated-fat percentage	High saturated fat during induction (kokosolie and butterfat).
Achieved lipids & lipoproteins	Serum cholesterol increased roughly five-fold during induction (approximately 830 ± 45 mg/dl). Regression (diet only): 210 ± 15 mg/dl. Diet + W-1372: 145 ± 10 mg/dl.
Arterial territories examined	Aorta, carotid bifurcations, femoral arteries, and main coronary branches.
Plaque-assessment method	Gross visual staining of the aortic surface, light microscopy, histomorphometry, and scanning electron microscopy.
Evidence of coronary disease	Advanced, occlusive fibro-lipid coronary plaques with prominent necrotic cores.
Evidence of plaque progression	Severe progressive plaques developed at 18 months, causing significant stenosis and media destruction.
Evidence of true regression	Marked reduction in gross aortic intimal lesion burden in the diet-only group, with further reduction when W-1372 was added. This is an aortic gross-surface endpoint rather than a direct morphometric measure of coronary plaque regression.
Evidence of plaque stabilization	Near-complete clearance of intracellular foam cells and a reduction in necrotic debris; endothelial-surface improvements were reported, in part in companion ultrastructural studies.
Calcification / thrombosis / death	Intraplaque hemorrhage and focal necrosis were present at baseline and were less evident in regression animals (inferred from cross-sectional necropsy comparisons).
Main conclusions	Advanced atherosclerotic plaques can regress; lowering plasma cholesterol toward baseline was associated with lesion regression and matrix stabilization, and the added pharmacologic agent was associated with greater lipid lowering and greater lesion improvement than diet alone.
Major limitations	Quantified primarily via visual surface-area projection and light microscopy.
Relevance to human disease	High; supported the concept that adding a pharmacologic agent to a lipid-lowering diet is associated with greater plaque improvement and endothelial repair than diet alone.

Rank 7: Oregon Alfalfa Saponin Program (Malinow, McLaughlin, Naito, McNulty, et al., 1978)

Full citation	[9] Malinow M. R., McLaughlin P., Naito H. K., Lewis L. A., McNulty W. P. Effect of alfalfa meal on shrinkage (regression) of atherosclerotic plaques during cholesterol feeding in monkeys. Atherosclerosis. 1978 May;30(1):27–43.
Year	1978
Primate species	Macaca fascicularis (Cynomolgus macaque)
Number of animals	72 (a baseline-necropsy group plus three groups of ~18 during the regression phase)
Sex and approximate age	Adult males, age approximately 5–6 years
Duration of atherogenic feeding	6 months
Duration of regression phase	18 months
Experimental diet composition	Semipurified diet rich in saturated fat, containing sucrose, dextrin, casein, and mineral mixtures.
Control / regression diet	Semipurified diet with or without alfalfa meal, or a diet consisting entirely of monkey chow.
Dietary cholesterol content	1.2 mg/Cal during induction; 0.34 mg/Cal in the subsequent semipurified diets, with or without alfalfa meal; the Monkey Chow comparison diet was nearly cholesterol-free.
Total-fat percentage	High fat (approximately 40% of calories) during induction; low fat during chow regression.
Saturated-fat percentage	High saturated fat during induction.
Achieved lipids & lipoproteins	Induction: 734 ± 41 mg/dl (TC). Alfalfa group: 341 ± 22 mg/dl. Chow group: 146 ± 11 mg/dl.
Arterial territories examined	Thoracic aorta, abdominal aorta, and main coronary arteries.
Plaque-assessment method	Visual surface staining of the aorta and histomorphometry of cross-sectioned coronary arteries.
Evidence of coronary disease	Extensive proximal coronary plaques with prominent lipid-laden foam cells.
Evidence of plaque progression	Monkeys on the control saturated-fat diet showed progressive, severe coronary plaques over the 18-month intervention period.
Evidence of true regression	Alfalfa-fed monkeys showed significant reduction in aortic and coronary plaque area, approaching the chow-fed group.
Evidence of plaque stabilization	Plaque shrinkage was accompanied by a marked decrease in foam cell infiltration and normalization of circulating lipoproteins.
Calcification / thrombosis / death	No prominent treatment toxicity was reported in the publication.
Main conclusions	Addition of alfalfa meal was associated with lower plasma cholesterol and reduced lesion burden during continued cholesterol feeding; saponin-mediated interference with intestinal sterol absorption was proposed as a mechanism, but the intervention was a complex plant preparation rather than a purified saponin.
Major limitations	The active component was not isolated; a whole plant preparation was used, and the coronary change was not necessarily quantified to the same standard as the aortic change.
Relevance to human disease	High; showed that an alfalfa-containing diet was associated with lower plasma cholesterol and reduced lesion burden during continued cholesterol feeding, while intestinal sterol-binding by saponins remained a proposed rather than an isolated mechanism.

Rank 8: Wake Forest / Bowman Gray Fatty Acid Program (Rudel, Parks, Sawyer, 1995)

Full citation	[10] Rudel L. L., Parks J. S., Sawyer J. K. Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects African green monkeys from coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2101–2110.
Year	1995
Primate species	Chlorocebus aethiops (African green monkey; formerly Cercopithecus aethiops)
Number of animals	36
Sex and approximate age	Adult males, age approximately 5–7 years
Duration of atherogenic feeding	5 years continuous feeding
Duration of regression phase	Comparative progression model (no dedicated regression phase in this cohort).
Experimental diet composition	Liquid-formula diet providing 35% of total kilocalories as fat, 21% from protein, and 44% from carbohydrate.
Control / comparison diets	Saturated fat (palm oil) vs. monounsaturated fat (oleic-enriched safflower) vs. polyunsaturated fat (standard safflower).
Dietary cholesterol content	0.80 mg/kcal in all experimental formulations.
Total-fat percentage	35.0% of total calories.
Saturated-fat percentage	Saturated group: 19.5%. Monounsaturated: 4.5%. Polyunsaturated: 5.1%.
Achieved lipids & lipoproteins	Saturated: 380 ± 25 (TC); Monounsaturated: 290 ± 18; Polyunsaturated: 280 ± 15 mg/dl. The monounsaturated group had the lowest LDL/HDL ratio yet did not show reduced atherosclerosis.
Arterial territories examined	Aorta, coronary arteries (LAD, LCx, RCA), and hepatic tissue.
Plaque-assessment method	Perfusion-fixed morphometry, chemical lipid-class separation, and hepatic ACAT activity assay.
Evidence of coronary disease	Advanced coronary atherosclerosis with prominent intimal plaque area in the saturated and monounsaturated groups.
Evidence of plaque progression	5 years of palm oil or oleic acid feeding drove progressive coronary plaque development.
Evidence of true regression	Comparative progression study; no regression phase. Polyunsaturated fat was associated with substantially less coronary plaque than monounsaturated or saturated fat.
Evidence of plaque stabilization	Polyunsaturated fat minimized cholesteryl ester and cholesteryl oleate accumulation in the coronary arteries.
Calcification / thrombosis / death	Plaqueverkalking was observed in the saturated and monounsaturated groups. No acute thrombotic events were documented.
Main conclusions	Under this cholesterol-containing experimental diet, monounsaturated fat did not reduce coronary plaque to the degree observed with polyunsaturated fat, despite apparently favorable plasma-lipoprotein measures; polyunsaturated fat minimized cholesteryl oleate accumulation. Findings cannot be extrapolated directly to whole-food human dietary patterns.
Major limitations	Absence of a dedicated regression or dietary crossover phase in this cohort.
Relevance to human disease	Very High; challenged the assumption that monounsaturated and polyunsaturated fats have equivalent cardiovascular effects.

Rank 9: Southwest Foundation Baboon Program (McGill, McMahan, Kruski, Mott, 1981)

Full citation	[11] McGill H. C. Jr., McMahan C. A., Kruski A. W., Mott G. E. Relationship of lipoprotein cholesterol concentrations to experimental atherosclerosis in baboons. Arteriosclerosis. 1981 Jan–Feb;1(1):3–12.
Year	1981
Primate species	Papio sp. (Baboon)
Number of animals	60
Sex and approximate age	Young adult males and females, age approximately 4–6 years
Duration of atherogenic feeding	26 months continuous feeding
Duration of regression phase	Baseline comparison design (diet-induced progression focus).
Experimental diet composition	Custom diet: 21% of calories from protein, 41% from fat, and 38% from carbohydrate.
Control diet	Low-fat standard baboon chow (approximately 5.8% calories from fat).
Dietary cholesterol content	1.7 mg/kcal during the 26-month experimental period.
Total-fat percentage	41.0% of total calories.
Saturated-fat percentage	17.2% of total calories (lard and dried egg yolk).
Achieved lipids & lipoproteins	Chow: 112 ± 8 mg/dl (TC). Atherogenic: 298 ± 15 mg/dl (TC).
Arterial territories examined	Thoracic aorta, abdominal aorta, common iliac, and extramural coronary arteries.
Plaque-assessment method	Perfusion-fixed visual surface estimation, independent pathobiological grading, and chemical lipid extraction.
Evidence of coronary disease	Mild-to-moderate early-stage coronary fatty streaks and small fibrous plaques.
Evidence of plaque progression	26 months of a high-saturated-fat, high-cholesterol diet drove aortic and coronary fatty-streak progression.
Evidence of true regression	Not directly evaluated in this study.
Evidence of plaque stabilization	No intervention or regression phase was tested; this was an association study. Plaque coverage was inversely correlated with HDL-cholesterol and positively with LDL+VLDL-cholesterol.
Calcification / thrombosis / death	No spontaneous thrombosis or myocardial infarctions reported; minimal baseline calcification observed.
Main conclusions	LDL + VLDL-cholesterol positively correlates, and HDL-cholesterol negatively correlates, with diet-induced plaque coverage in baboons.
Major limitations	Minimal development of advanced, stenotic coronary disease within 2 years.
Relevance to human disease	High; demonstrated associations between lipoprotein-cholesterol fractions and lesion burden under controlled conditions. These observational relationships do not establish HDL-cholesterol as a causal, modifiable treatment target.

 

Rank 10: Oregon New World Program (Maruffo & Portman, 1968)

Full citation	[2] Maruffo C. A., Portman O. W. Nutritional control of coronary artery atherosclerosis in the squirrel monkey. J Atheroscler Res. 1968 Mar–Apr;8(2):237–247.
Year	1968
Primate species	Saimiri sciureus (Squirrel monkey)
Number of animals	24
Sex and approximate age	Adult males and females, wild-caught (age unknown)
Duration of atherogenic feeding	3–12 months
Duration of control-diet follow-up	3–12 months
Experimental diet composition	Semipurified diet rich in saturated fat, containing lard and butter.
Control diet	Low-fat, cholesterol-free standard commercial grain-based diet.
Dietary cholesterol content	0.5% to 1.0% by weight during induction; cholesterol-free during the control-diet period.
Total-fat percentage	High fat (approximately 35% of calories) during induction; low fat during the control period.
Saturated-fat percentage	High saturated fat during induction (lard and butter).
Achieved lipids & lipoproteins	Induction: greater than 400 mg/dl (TC); plasma cholesterol fell rapidly toward baseline after return to the control diet.
Arterial territories examined	Thoracic aorta, abdominal aorta, and extramural coronary arteries.
Plaque-assessment method	Histopathology, electron microscopy, and tissue lipid-class separation.
Evidence of coronary disease	Early, lipid-rich coronary atheromas with prominent intimal foam-cell accumulations.
Evidence of plaque progression	High-cholesterol feeding caused rapid progression of aortic and coronary fatty streaks.
Evidence of true regression	Return to a low-fat, cholesterol-free diet arrested progression; the extent of true anatomical regression of early lesions is characterized cautiously (see note in Methodological Critique).
Evidence of plaque stabilization	Reduced plaque lipid content, with thin, fibro-elastic intimal thickenings persisting.
Calcification / thrombosis / death	No acute coronary thrombotic events or myocardial infarctions were documented during the study.
Main conclusions	The study supports arrest of progression and reduced lesion lipid content after dietary normalization more clearly than it supports quantitatively proven anatomical regression of early lesions.
Major limitations	Small vessel caliber and physical dimension constraints limited detailed functional vascular evaluation.
Relevance to human disease	Moderate-High; supported the concept that early-stage coronary lesions have high metabolic plasticity.

Dietary Interventions and Macronutrient Analysis

Analyzing the dietary interventions used in nonhuman primate studies reveals the specific nutritional drivers of atherogenesis and regression. Historical experiments systematically evaluated the interactions of total fat, saturated fat, polyunsaturated fat, and cholesterol, providing insights that go beyond simple “high-fat” versus “low-fat” categorization.

Saturated vs. Polyunsaturated Fatty Acids in Progression and Regression

A primary question of the 1970s and 1980s was whether reversing atherosclerosis required a very-low-fat diet, or if a diet rich in polyunsaturated fat could achieve similar outcomes. In the landmark rhesus macaque study by Armstrong et al., the progression phase was driven by a diet containing 41% of total calories from fat, primarily from dried egg yolk, which produced severe, diffuse coronary stenosis.

During the 40-month regression phase, investigators compared a low-fat diet (4% of total calories from fat, primarily from grain starch) with a high-polyunsaturated-fat diet (40% of total calories from corn oil, rich in linoleic acid). Both diets were entirely cholesterol-free. The outcomes of this head-to-head comparison were striking:

• Both diets reduced plasma total cholesterol to nearly identical levels (approximately 140 mg/dl).
• Both diets reversed the atherogenic beta-lipoprotein-dominant (LDL) profile back toward alpha-lipoprotein dominance (the historical electrophoretic correlate of the HDL fraction, which is not identical to today’s HDL subclasses).
• Anatomical coronary regression was similar between the groups: the average cross-sectional lumen area was more than 80% greater in regression animals than in animals with baseline disease, with no significant difference between the low-fat and corn-oil diets. The decisive shared feature was not the total-fat content but the fact that both diets normalized circulating cholesterol, LDL, and (by inference) the ApoB-particle burden; regression followed that normalization.

In this model, very low total fat was not necessary for regression: a cholesterol-free, polyunsaturated-fat-rich diet produced an equivalent and sustained reduction in circulating atherogenic lipoproteins and comparable regression. The experiment therefore identifies the achieved lipoprotein response—rather than total-fat percentage alone—as the factor most closely associated with regression. It does not establish that total dietary fat is irrelevant across other species, fatty-acid compositions, energy intakes, or ordinary human diets; the effects of saturated fat and dietary cholesterol on circulating ApoB are substantial but not deterministic.

The Confounding Roles of Casein, Sucrose, and Caloric Intake

Evaluating historical primate experiments requires separating the effects of dietary fat and cholesterol from other ingredients in semipurified diets. Many atherogenic formulas contained casein as the sole protein source and sucrose as the primary carbohydrate, both of which can have independent metabolic effects.

Casein has been reported to raise plasma cholesterol in several mammalian species compared with soy or other plant proteins, an effect that varies considerably by species and is possibly related to differences in amino-acid composition and in cholesterol and bile-acid metabolism. Refined sucrose does not by itself produce atherosclerotic plaque, but high intakes raise hepatic VLDL synthesis, plasma triglyceriden, and remnant lipoproteins and may worsen an atherogenic lipoprotein profile. Furthermore, many primate studies allowed ad libitum feeding, resulting in positive energy balance and weight gain, which can confound metabolic assessments. A related caution applies to the cholesterol-free regression diets used across these programs: because such diets often changed fat source, fat percentage, energy density, protein source, vezel, and plant compounds simultaneously, readers should not infer that dietary cholesterol alone accounts for either disease induction or its reversal.

However, in trials that controlled for these variables—such as the LSU rhesus program, which used identical casein, sucrose, and fat levels in both the progression and regression feeds, varying only the cholesterol content—deleting cholesterol while holding saturated fat high was sufficient to lower plasma cholesterol and induce regression. This underscores the central role of dietary cholesterol in this model, while not excluding independent contributions of saturated fat that have been demonstrated in other experimental designs.

Progression and Regression Dynamics: Plaque vs. Stabilization

Diet-induced atherosclerosis in nonhuman primates follows a predictable pathological sequence that closely mirrors the development of human coronary artery disease.

ApoB-particle entry & retention → aggregation & biochemical modification → endothelial / innate immune activation → lipid loading of macrophage- and smooth-muscle-derived foam cells → extracellular lipid, matrix remodeling, cell death & defective efferocytosis → fibrous cap / necrotic core

Pathological Milestones of Progression

• Endothelial Activation & Fatty Streaks: Elevated circulating ApoB particles are retained in the subendothelial space, where they undergo aggregation, oxidation, and other biochemical modifications. This triggers endothelial adhesion molecules and recruits blood-derived monocytes, which differentiate into macrophages and internalize modified lipoproteins to become foam cells, forming early fatty streaks.
• Fibrous Plaque Development: Under continued hypercholesterolemia, foam cells release growth factors (such as platelet-derived growth factor) that stimulate smooth muscle cell migration from the media. These cells proliferate and secrete extracellulaire matrix proteins, creating a fibrous cap over the lipid-rich core; smooth-muscle-derived cells can themselves take up lipid and contribute substantially to the foam-cell population.
• Necrotic Core Formation: As the plaque matures, foam cells within the core undergo apoptosis and secondary necrosis. Failure of efferocytosis leads to accumulation of cellular debris, free cholesterol, and lipid pools, forming a highly unstable necrotic core.
• Calcification and Media Changes: Microscopic calcium granules emerge within the necrotic core and degenerating smooth muscle cells and coalesce into large, rigid mineral plates. The adjacent tunica media often exhibits cellular infiltration, elastic lamina fragmentation, and focal thinning.

Plaque Stabilization vs. Anatomical Shrinkage

• Macrophage Depletion and Inflammatory Resolution: Marked lipid lowering reduces continued monocyte recruitment and promotes the loss, clearance, and phenotypic remodeling of plaque macrophages; the relative contributions of emigration, cell death, and efferocytosis vary by model and lesion stage. Macrophages downregulate inflammatory genes and upregulate tissue-remodeling markers, and necrotic debris is progressively removed as local ontsteking resolves.
• Matrix Remodeling & Fiber Cross-Linking: While lipid and cellular components are cleared comparatively more quickly, extracellular matrix elements (collagen, elastin) are remodeled more slowly. Smooth muscle cells synthesize new collagen fibers that cross-link and condense, transforming a soft, unstable atheroma into a flatter, more stable, fibrous lesion.
• Endothelial Healing: The endothelial lining over remaining plaque recovers structural integrity, forming continuous, tightly joined cell junctions that resist shear stress and reduce thrombogenicity.

These changes indicate that plaque stabilization and structural healing precede, and can occur independently of, a significant reduction in overall plaque size.

In modern mechanistic terms, the removal of plaque lipid during regression is understood to depend heavily on reverse cholesterol transport: efflux of free cholesterol from lipid-laden cells via the transporters ABCA1 and ABCG1 to HDL acceptors, esterification by lecithin–cholesterol acyltransferase (LCAT), and ultimate hepatic clearance. These efflux pathways were not directly measured in the historical primate experiments, but they provide the contemporary biochemical framework for the lipid depletion those studies documented morphologically and chemically.

Macromolecular and Kinetic Mechanisms (ApoB and the Cumulative-Exposure Model)

ApoB-Containing Lipoproteins and Cumulative Arterial Exposure

The entry and subsequent retention of ApoB-containing lipoproteins within the subendothelial space constitute the fundamental initiating lipid event in atherosclerotic plaque formation. LDL, intermediate-density lipoproteins, cholesterol-enriched remnants, and lipoproteïne(a) can cross the arterial endotheel. Once within the intima, positively charged regions of apolipoprotein B interact with negatively charged glycosaminoglycan chains on arterial-wall proteoglycans (notably biglycaan en versican), selectively retaining these particles at lesion-prone sites [12]. Retained particles undergo aggregation, enzymatic modification, oxidation, and other compositional changes that provoke innate and adaptive immune responses, macrophage foam-cell formation, smooth-muscle-cell phenotypic change, extracellular lipid accumulation, and ultimately formation of a fibrous and potentially necrotic plaque. Because each atherogenic LDL, IDL, remnant, or Lp(a) particle carries a single ApoB molecule, it is the number of retained particles—not the cholesterol mass they carry—that is mechanistically trapped in the wall; this is why particle-based (ApoB) measures are conceptually preferable to cholesterol-mass (LDL-C) measures, even though the historical studies could report only the latter.

Hemodynamic forces, endothelial transcytosis, arterial proteoglycan composition, inflammation, and genetic susceptibility strongly influence the location and rate of lesion development. These factors do not displace ApoB-bevattende deeltjes from the causal center of atherogenesis; rather, they regulate the probability that circulating particles will enter, remain within, and injure a particular arterial region. In this framework, ApoB deeltjesbelasting supplies the atherogenic substrate, arterial-wall characteristics govern retention and biological response, and inflammatory and thrombotic pathways determine plaque progression and clinical complication.

The progression of atherosclerosis is therefore influenced by cumulative arterial exposure to circulating ApoB-containing particles. This relationship may be represented conceptually as:

Cumulatieve blootstelling = ∫₀^t C_ApoB(t) dt

where C_ApoB(t) is the circulating concentration of atherogenic ApoB-containing particles over time. The equation is not intended to imply that identical calculated exposure produces identical plaque in every individual. The biological consequences of a given exposure are modified by particle composition, arterial-wall retention affinity, age, blood pressure, roken, glycemia, inflammation, hemodynamics, and genetic susceptibility. Nevertheless, the primate literature is consistent with, and provides experimental support for, the cumulative ApoB-exposure model derived from modern human genetic, epidemiologic, and clinical evidence [13], [14]: longer and greater exposure produces older, more fibrotic, calcified, and metabolically resistant lesions, whereas early lipid-rich lesions remain substantially more reversible.

Most historical primate studies measured plasma total cholesterol, beta-lipoprotein cholesterol, or LDL-plus-VLDL cholesterol rather than ApoB directly. Their findings can nevertheless be interpreted within the modern ApoB framework because the atherogenic diets produced marked increases in circulating ApoB-containing lipoproteins, while successful regression regimens produced large and sustained reductions in those particles. The close relationship between normalization of the atherogenic lipoprotein burden and plaque arrest, lipid depletion, stabilization, and partial anatomical regression provides experimental support for the causal importance of cumulative ApoB exposure.

The LSU long-term rhesus studies illustrate this principle: animals exposed to a sustained lipid challenge over 5.4 years developed highly complex, fibrotic, structured plaques that needed a substantially longer duration of lipid lowering (regression becoming demonstrable at approximately 3.7 years) than early lipid-rich lesions, indicating that the physical age of a plaque, combined with its cumulative exposure history, influences its metabolic reversibility.

Comparative Analysis with Human Pathology and Clinical Trials

Translating the pathological findings of historical primate experiments to human clinical practice requires a careful evaluation of the shared pathways and structural differences between these models and human disease.

Structural Parallels and Shared Mechanisms

The cellular and molecular mechanisms of atherogenesis are highly conserved between humans and nonhuman primates. Both species initiate plaque formation through the subendothelial retention and oxidation of ApoB-containing lipoproteins. Subsequent steps—including monocyte migration, differentiation into macrophages, scavenger-receptor-mediated lipid uptake, smooth muscle cell migration, and necrotic core formation—are closely similar in both species. Under prolonged dietary challenge, both rhesus and cynomolgus macaques develop advanced plaques characterized by fibrous caps, lipid cores, calcification, and media degradation, resembling advanced (complicated) human atherosclerotic lesions. Although histologically similar, experimentally induced monkey plaques typically remain simpler than many decades-old human plaques that have been exposed to multiple, concurrent cardiovascular risicofactoren.

Shared Clinical and Pathological Consequences

• Myocardial Infarction: Rare spontaneous, fatal myocardial infarctions were reported in some long-term, severely hypercholesterolemic macaque colonies. A frequently cited estimate is roughly 1 per 300 monkeys at risk per year [15], [16]; this figure derives from a commentary rather than a directly analyzed incidence cohort and should not be generalized across species or protocols. Where they occurred, these infarctions were morphologically similar to human infarcts, showing transmural or subendocardial necrosis, contraction band necrosis, and associated electrocardiographic changes.
• Vascular Reactivity & Vasomotor Tone: Both species exhibit impaired endothelial stikstofoxide (NO) bioavailability during atherogenesis. Under hypercholesterolemic conditions, coronary arteries lose their ability to dilate in response to acetylcholine (instead exhibiting paradoxical vasoconstriction), a defect that, in studies that directly measured vascular reactivity, was reversible upon sustained lipid lowering.
• Cerebrovascular & Peripheral Disease: Monkeys fed atherogenic diets develop atherosclerosis in extracoronary arteries such as the carotid bifurcation and the femoral arteries, mimicking the systemic distribution of human arterial disease.

Plaque Remodeling: Primate vs. Human Imaging Outcomes

Evaluating regression in human klinische onderzoeken relies on non-invasive imaging technologies that assess specific dimensions of plaque biology. Nonhuman primate studies provide the histopathological verification that underpins the interpretation of these clinical endpoints.

• Lumen Diameter (QCA): Early human trials used quantitative coronary angiography to measure change in luminal diameter, occasionally documenting small improvements. Quantitative coronary angiography records luminal dimensions and cannot by itself distinguish plaque shrinkage from changes in arterial remodeling (the outward, plaque-compensating enlargement first characterized by Glagov [17]) or vasomotor tone; primate studies show that lipid lowering can improve lumen dimensions and vascular reactivity without a proportionate reduction in histological plaque area.
• Total Plaque Volume (IVUS & OCT): Modern trials use intravasculaire echografie en optical coherence tomography to measure changes in total plaque volume, often showing small reductions. Primate studies suggest these reductions represent cellular and chemical clearance of lipid pools and necrotic debris from the plaque core.
• Noncalcified Plaque Changes (CCTA): Coronary CT angiography allows non-invasive quantification of soft, noncalcified plaque volume. Primate data indicate this pool contains highly active, lipid-laden foam cells and extracellular lipid deposits, which are the most rapidly cleared components during regression. Consistent with modern IVUS and CCTA observations, an increase in calcium density can accompany this loss of lipid-rich plaque during healing, so a rising calcium signal does not necessarily indicate disease progression.
• Vulnerable Plaque Features & Healing: OCT and PET imaging in humans track fibrous-cap thickening, necrotic-core reduction, and stabilization of inflamed plaques. Nonhuman primate histopathology is consistent with these findings, showing improved endothelial coverage, reduced foam-cell populations, and deposition of a denser, more stable collagen cap over remaining necrotic debris; whether foam-cell loss reflects emigration, local cell death, reduced recruitment, or efflux was not resolved in most historical studies.

The primate findings sit within a broader modern framework. The response-to-retention hypothesis formalized subendothelial ApoB-particle retention as the initiating step [12]; human Mendelian-randomization and epidemiologic work established cumulative LDL/ApoB exposure as a determinant of lifetime risk [13], [14]; and the inflammatory contribution to events was confirmed clinically in the CANTOS trial [18]. In parallel, serial intravascular-imaging and CT trials of intensive lipid lowering—REVERSAL [19], ASTEROÏDE [20], Saturnus [21], GLAGOV [22], PACMAN-AMI [23], and HUYGENS [24]—have documented plaque regression, stabilization, and compositional change in living patients, connecting the historical primate evidence to contemporary human data.

Methodological and Ethical Critique

Evaluating historical primate literature requires a critical analysis of both the experimental designs of the mid-to-late twentieth century and the evolution of contemporary animal welfare regulations.

Methodological Limitations and Design Bias

• Cross-Sectional Postmortem Comparisons: Most historical regression studies relied on a cross-sectional design in which a subgroup of animals was necropsied at the end of induction to establish “baseline progression,” and the remaining animals were randomized to regression arms and evaluated years later. This design assumes the baseline group is representative of the surviving regression animals. Given the high individual variation in dietary response (the “hyper-responder” versus “hypo-responder” phenomenon), it can introduce significant statistical noise and bias.
• Survivorship Bias: In long-term progression studies, animals with the most severe coronary stenosis were at high risk for plotselinge hartdood before the formal regression phase, which can lead to selective evaluation of more resistant, hypo-responsive animals in the final regression cohorts.
• Small Sample Sizes: Because of the high cost and complexity of primate husbandry, many cohorts were small (often 6 to 12 per arm), limiting statistical power and complicating subgroup analyses.
• Colony Overlap and Duplicate Reporting: Investigators frequently generated multiple, overlapping publications from the same cohorts over several years, making it difficult to isolate independent experimental results in systematic reviews.
• Note on Maruffo & Portman (1968): Secondary summaries of this early squirrel-monkey work describe a comparatively short atherogenic period followed by a control-diet period in which lesions did not progress but did not clearly regress. The extent of true anatomical regression in this specific study should therefore be characterized cautiously and confirmed against the primary report.

Historical Terminology vs. Modern Usage

• “Cholesterol Atherosclerosis” & “Atheromatosis”: Historically used to describe the diffuse lipid-loading and foam cell infiltration driven by extreme dietary cholesterol feeding. Modern pathology reserves “atherosclerosis” for the complex, chronic, inflammatory-fibromuscular disease process, distinguishing it from simple, non-inflammatory intimal lipid deposition.
• “Beta-Lipoproteinemia”: Refers to the historical electrophoretic classification of circulating lipoproteins, where beta-lipoproteins corresponded to the LDL fraction and alpha-lipoproteins to the HDL fraction. These electrophoretic bands are not identical to the density-defined subclasses of modern lipidology; contemporary biochemistry uses density ultracentrifugation and immunoassays to directly quantify specific apolipoprotein particles, particularly ApoB and ApoA-I. The historical primate targets (for example, a total-cholesterol ceiling near 200 mg/dl) also predated routine ApoB measurement.
• “Regression”: Historically defined as any reduction in visual arterial lesion coverage or tissue cholesterol content. Modern vascular biology distinguishes true volumetric regression from structural stabilization, fibrous-cap reinforcement, and functional vasomotor recovery.

Ethical Evolution of Primate Research Regulations

The regulatory landscape governing animal research underwent a profound transformation during this era. The original United States Laboratory Animal Welfare Act of 1966 was primarily enacted to regulate the transport, sale, and handling of six species, including nonhuman primates, to prevent pet theft and ensure basic humane care. A 1970 amendment renamed the statute the Animal Welfare Act and broadened coverage toward warm-blooded animals used in research, with a further amendment in 1976.

The most extensive regulatory shift occurred with the 1985 Improved Standards for Laboratory Animals Act, enacted as part of the Food Security Act of 1985. This amendment introduced requirements that altered the design of primate research:

• Institutional Animal Care & Use Committees (IACUCs): Mandated independent review boards to evaluate and approve experimental protocols involving covered species, ensuring that pain and distress are minimized.
• Environmental Enrichment & Psychological Well-Being: Required institutions to develop plans promoting the psychological well-being of nonhuman primates, with environmental enrichment and, where appropriate, compatible social housing among the preferred measures rather than an unconditional requirement for every animal.
• Reduction & Alternatives: Compelled researchers to formally consider alternatives to painful procedures and to minimize the number of animals used.

Simultaneously, the Health Research Extension Act of 1985 amended the Public Health Service Act and provided the statutory basis for the PHS Policy on Humane Care and Use of Laboratory Animals, enforcing compliance with the Guide for the Care and Use of Laboratory Animals for NIH-funded institutions. These regulatory changes, combined with rising financial costs and international conservation measures, sharply curtailed the large-scale, invasive primate experiments of the mid-twentieth century. Modern research relies heavily on non-invasive imaging and highly refined, ethically approved protocols.

Explicit Investigation of Core Hypotheses and Counter-Evidence

To evaluate the scientific integrity of the primate literature, the core hypotheses of this field are examined below alongside the evidence that supports and challenges each.

Hypothesis 1: Nonhuman primates develop coronary atherosclerosis that is histologically and metabolically closer to human disease than most other laboratory animals.

Support. Rhesus and cynomolgus macaques develop complex epicardial coronary plaques featuring fibrous caps, lipid-rich necrotic cores, calcification, media degradation, and spontaneous myocardial infarctions that closely match human lesions.

Counter-Evidence / Challenges. Certain species, such as baboons and squirrel monkeys, are relatively resistant to severe, occlusive coronary stenosis or advanced plaque rupture within standard timeframes, limiting their utility for modeling late-stage clinical events.

Hypothesis 2: Diet-induced elevations in ApoB-containing lipoproteins are the principal mediator between atherogenic diets and plaque formation.

Support. Plaque progression and regression correlate strongly with circulating VLDL+LDL-cholesterol, and clearing these ApoB-containing particles is required to arrest and reverse plaque development.

Counter-Evidence / Challenges. Local proteoglycan binding, hemodynamics, and chemical modifications (such as oxidation) are also required to initiate plaque formation. Some animals show significant variation in lesion severity at identical circulating ApoB levels, indicating individual genetic and vascular susceptibility.

Hypothesis 3: Early lipid-rich lesions can regress substantially after major cholesterol reduction.

Support. Early fatty streaks and foam-cell-rich lesions in rhesus and squirrel monkeys undergo rapid and substantial regression within months following a return to low-cholesterol diets.

Counter-Evidence / Challenges. In advanced, highly structured lesions, simple lipid lowering may clear intracellular cholesteryl esters but does not rapidly reduce overall plaque cross-sectional area, as the mature collagenous and calcified matrix remains largely unchanged.

Hypothesis 4: Advanced fibrotic or calcified lesions regress incompletely but may become more stable.

Support. Long-term regression studies show that while advanced, years-old plaques lose inflammatory cell content and soft lipid pools, dense collagenous scars and large calcified plates persist within the arterial wall.

Counter-Evidence / Challenges. Under certain long-term protocols, very slow reductions in plaque calcium and enzymatic degradation of collagen have been reported, indicating that even mature matrix components possess slow, long-term turnover.

Hypothesis 5: The duration and cumulative magnitude of lipoprotein exposure influence whether plaque is reversible.

Support. LSU studies showed that regression of plaques induced over 5.4 years became statistically demonstrable only after an extended regression phase (approximately 3.7 years), in contrast to the more rapid response of early fatty streaks.

Counter-Evidence / Challenges. In some experiments, genetic “hypo-responder” animals showed significant regression under moderate lipid lowering, whereas “hyper-responders” progressed, indicating that individual metabolic susceptibility can override cumulative-exposure targets.

Hypothesis 6: Very-low-fat diets promote regression primarily when they produce large and sustained reductions in atherogenic lipoproteins.

Support. Reversing hypercholesterolemia using ultra-low-fat diets (4% of calories as fat) lowers plasma cholesterol and regresses coronary plaques.

Counter-Evidence / Challenges. Corn-oil-substitution diets (40% of calories as fat) achieve comparable plasma cholesterol lowering and coronary regression when dietary cholesterol is eliminated, indicating that absolute lipid clearance, rather than total dietary fat reduction, is the primary driver.

Hypothesis 7: Human coronary regression is generally smaller and slower than in some monkey studies because human plaques are older, more heterogeneous, and exposed to multiple risk factors.

Support. Human plaques accumulate over decades and are characterized by highly cross-linked, mature collagen and calcification. Diet-induced monkey lesions are typically generated over 1 to 5 years and contain younger, more metabolically active lipids that are more easily cleared.

Counter-Evidence / Challenges. Aggressive modern pharmacological regimens can lower human LDL-cholesterol to very low levels, which has been associated with rapid regression of soft, noncalcified lipid cores, approaching the kinetics seen in some primate studies.

Hypothesis 8: Clinical benefit may result more from plaque stabilization and prevention of new lesions than from complete removal of existing plaque.

Support. Primate lipid-lowering trials demonstrated an approximate doubling of coronary artery and lumen cross-sectional area, consistent with favorable outward remodeling, together with improved endothelium-dependent vasomotor dilation to acetylcholine, despite persistence of the advanced calcified plaque matrix.

Counter-Evidence / Challenges. While stabilization reduces acute ischemic events, more complete anatomical reduction of plaque may still be needed to restore normal mechanical vascular compliance and relieve severe, chronic exertional angina in highly stenotic vessels.

What These Animal Studies Do Not Prove

To ensure rigorous translation to human clinical practice, the scientific and biological limits of nonhuman primate trials must be clearly defined:

• They do not prove that diet alone can reverse advanced coronary artery disease in all humans. Primate studies used highly controlled, extreme dietary changes (such as shifting from a high-fat, high-cholesterol diet to an entirely cholesterol-free diet) under laboratory conditions that are difficult for human patients to achieve or sustain.
• They do not prove that coronary artery calcium will disappear. Historical pathology demonstrated that while lipid-rich pools and cell debris can be cleared, large, consolidated calcific deposits persist within the vessel wall, undergoing little to no anatomical regression over several years of lipid normalization. Calcification is not a single quantity: frequency, calcified area, microverkalking, macrocalcified plates, and calcium density can change independently, and in human therapy an increase in calcium density can accompany reduction of lipid-rich plaque and lower event rates, so persistent or increasing calcium does not by itself indicate treatment failure.
• They do not prove that human plaques regress at the same speed as monkey plaques. Nonhuman primates have significantly shorter lifespans and higher metabolic rates. A 3-year regression period in a rhesus monkey represents a substantial fraction of its lifespan, whereas human plaques develop over decades and are exposed to multiple, often unmanaged risk factors.
• They do not prove the human safety or efficacy of high-dose alternative agents. While plant-derived saponins or alfalfa meal induced regression in cynomolgus monkeys by blocking intestinal absorption, such agents can cause systemic toxicities (such as hemolytic effects) in humans if not carefully purified, and they are not approved for clinical use.

Unanswered Questions and Contemporary Experimental Opportunities

Critical Unanswered Questions

• What is the precise phenotypic fate of plaque smooth muscle cells during dietary regression, and do they revert from a synthetic, proliferative state back to a contractile state?
• How does systemic inflammation (measured by high-sensitivity C-reactieve proteïne or key interleukins) interact with aggressive lipid-lowering diets to determine the speed of primate coronary regression?
• Can advanced coronary microvascular dysfunction be fully reversed by intensive dietary modification alone, or does it require concurrent pharmacotherapy?

Contemporary, Highly Ethical Experimental Designs

Studies involving prolonged ernstige hypercholesterolemie, substantial morbidity, or terminal pathological assessment would now face far more demanding scientific-necessity, harm–benefit, refinement, veterinary-monitoring, and IACUC review; such work is not categorically prohibited, but many historical protocols would be difficult to justify or would require substantial redesign. Within these constraints, highly informative, minimally invasive studies can be conducted in nonhuman primates today:

• Serial, Non-Invasive High-Resolution Imaging: High-resolution MRI, PET/CT, and coronary CT angiography can track progression and regression within the same living animals over time, eliminating the statistical noise of cross-sectional designs and enabling real-time evaluation of plaque volume, lipid content, and calcification.
• Pedigreed, Aged Nonhuman Primate Colonies: Established, naturally occurring hyperlipidemic or aged primate cohorts allow evaluation of gene-diet interactions and the impact of aging on plaque stability without invasive surgery or rapid, unphysiological lipid-loading regimens.
• Peripheral Blood Transcriptomics and Biomarkers: Single-cell RNA sequencing of peripheral blood mononuclear cells and circulating inflammatory markers during dietary interventions can map the systemic immune and metabolic pathways that drive vascular healing and reverse cholesterol transport.

Central Synthesis and Answer to the Central Question

Question. To what extent do historical monkey experiments demonstrate that human-like coronary atherosclerosis caused by prolonged exposure to elevated atherogenic lipoproteins can be slowed, stabilized, or partially reversed through major dietary and plasma-lipid reduction, and what aspects of those findings can and cannot reasonably be extrapolated to human coronary artery disease?

Historical nonhuman primate experiments between 1950 and the late 1980s provide histologically verified evidence that human-like coronary atherosclerosis is a dynamic and potentially reversible pathology. These trials demonstrate that when severe hypercholesterolemia is aggressively reversed, the progression of coronary atheromas is arrested and substantial anatomical regression can be achieved. Early, lipid-rich plaques possess high metabolic plasticity, allowing rapid clearance of intracellular foam cells, hydrolysis of cholesteryl esters, and resolution of early-stage stenosis within months.

By contrast, advanced, calcified, and densely fibrotic plaques regress much more slowly and incompletely, leaving a persistent collagenous scar and mineral deposits within the vessel wall. Crucially, these studies show that the clinical benefits of lipid lowering are not restricted to physical plaque shrinkage. Substantial benefit results from plaque stabilization—including lipid depletion, reduced cellularity and inflammation, increased relative collagen content, endothelial healing, and (in modern human imaging studies) fibrous-cap thickening—together with enlargement of coronary artery and lumen cross-sectional area consistent with favorable remodeling and improved endothelium-dependent vasomotor dilation.

Extrapolatable Findings

• The Shared Cellular Mechanics of Reversal: The core pathways of ApoB retention, foam-cell reduction, cholesterol efflux, fibrous-cap reinforcement, and endothelial healing are broadly conserved between primates and humans, supporting the biological plausibility of clinical plaque stabilization.
• The Targets of Volumetric Change: Soft, noncalcified, lipid-rich plaque cores are the most rapidly and completely cleared components during regression, matching human intravascular imaging findings.
• Outward Remodeling & Functional Vasomotor Recovery: The primate finding that lipid lowering can approximately double the coronary artery and lumen cross-sectional area and improve endothelial reactivity helps explain why human cardiovascular event rates decline following lipid-lowering therapy despite minimal overall change in angiographic stenosis.

Non-Extrapolatable Findings

• The Kinetics and Speed of Regression: Human coronary plaques are older, more structurally complex, and characterized by highly cross-linked, mature collagen and calcification. They are less metabolically active and regress much more slowly than the younger, diet-induced lesions of experimental primates.
• The Complexity of Multi-Risk Etiologies: Primate trials examined a single, severe, diet-induced risk factor under uniform conditions. Human coronary artery disease is multifactorial, driven by the interaction of lipid levels with cigarette smoking, hypertensie, diabetes, and genomic variation.
• The Feasibility of Extreme Dietary Reversals: The extreme dietary changes used to drive regression in primate trials are difficult to achieve or sustain in clinical practice, requiring human therapies to rely on a combination of moderate dietary modification and intensive pharmacological lipid-lowering.
• No Endorsement of a Specific Named Diet: These experiments do not establish that any particular human dietary program—Ornish, Esselstyn, vegan, or Mediterranean—is superior. What they demonstrate is narrower and mechanism-based: aggressive, sustained reduction of atherogenic (ApoB-containing) lipoproteins, by whatever means, can arrest progression and induce regression under controlled conditions.

Referenties

1. TAYLOR CB, PATTON DE, COX GE. ATHEROSCLEROSIS IN RHESUS MONKEYS. VI. FATAL MYOCARDIAL INFARCTION IN A MONKEY FED FAT AND CHOLESTEROL. Arch Pathol. 1963;76:404-412.
2. Maruffo CA, Portman OW. Nutritional control of coronary artery atherosclerosis in the squirrel monkey. J Atheroscler Res. 1968;8(2):237-247. doi:10.1016/s0368-1319(68)80060-2
3. Armstrong ML, Warner ED, Connor WE. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970;27(1):59-67. doi:10.1161/01.res.27.1.59
4. Vesselinovitch D, Wissler RW, Hughes R, Borensztajn J. Reversal of advanced atherosclerosis in Rhesus monkeys. Part 1. Light-microscopic studies. Atherosclerosis. 1976;23(2):155-176. doi:10.1016/0021-9150(76)90092-7. Cited jointly as [4] with the companion ultrastructural report: Weber G, Fabbrini P, Resi L, Jones R, Vesselinovitch D, Wissler RW. Regression of arteriosclerotic lesions in rhesus monkey aortas after regression diet. Scanning and transmission electron microscope observations of the endothelium. Atherosclerosis. 1977;26(4):535-547. doi:10.1016/0021-9150(77)90121-6
5. Clarkson TB, Bond MG, Bullock BC, McLaughlin KJ, Sawyer JK. A study of atherosclerosis regression in Macaca mulatta. V. Changes in abdominal aorta and carotid and coronary arteries from animals with atherosclerosis induced for 38 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Exp Mol Pathol. 1984;41(1):96-118. doi:10.1016/0014-4800(84)90011-x
6. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984;73(6):1590-1605. doi:10.1172/JCI111366
7. Williams JK, Anthony MS, Honoré EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 1995;15(7):827-836. doi:10.1161/01.atv.15.7.827
8. Strong JP, Bhattacharyya AK, Eggen DA, Malcom GT, Newman WP 3rd, Restrepo C. Long-term induction and regression of diet-induced atherosclerotic lesions in rhesus monkeys. I. Morphological and chemical evidence for regression of lesions in the aorta and carotid and peripheral arteries. Arterioscler Thromb. 1994;14(6):958-965. doi:10.1161/01.atv.14.6.958. Companion paper, cited jointly as [8]: Strong JP, Bhattacharyya AK, Eggen DA, Stary HC, Malcom GT, Newman WP 3rd, Restrepo C. Long-term induction and regression of diet-induced atherosclerotic lesions in rhesus monkeys. II. Morphometric evaluation of lesions by light microscopy in coronary and carotid arteries. Arterioscler Thromb. 1994;14(12):2007-2016. doi:10.1161/01.atv.14.12.2007
9. Malinow MR, McLaughlin P, Naito HK, Lewis LA, McNulty WP. Effect of alfalfa meal on shrinkage (regression) of atherosclerotic plaques during cholesterol feeding in monkeys. Atherosclerosis. 1978;30(1):27-43. doi:10.1016/0021-9150(78)90150-8
10. Rudel LL, Parks JS, Sawyer JK. Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects African green monkeys from coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15(12):2101-2110. doi:10.1161/01.atv.15.12.2101
11. McGill HC Jr, McMahan CA, Kruski AW, Mott GE. Relationship of lipoprotein cholesterol concentrations to experimental atherosclerosis in baboons. Arteriosclerosis. 1981;1(1):3-12. doi:10.1161/01.atv.1.1.3
12. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551-561. doi:10.1161/01.atv.15.5.551
13. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
14. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313-2330. doi:10.1093/eurheartj/ehz962
15. Clarkson TB, Mehaffey MH. Coronary heart disease of females: lessons learned from nonhuman primates. Am J Primatol. 2009;71(9):785-793. doi:10.1002/ajp.20693
16. Bond MG, Bullock BC, Bellinger DA, Hamm TE. Myocardial infarction in a large colony of nonhuman primates with coronary artery atherosclerosis. Am J Pathol. 1980;101(3):675-692.
17. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371-1375. doi:10.1056/NEJM198705283162204
18. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
19. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-1080. doi:10.1001/jama.291.9.1071
20. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. doi:10.1001/jama.295.13.jpc60002
21. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-2087. doi:10.1056/NEJMoa1110874
22. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. doi:10.1001/jama.2016.16951
23. Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-1781. doi:10.1001/jama.2022.5218
24. Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022;15(7):1308-1321. doi:10.1016/j.jcmg.2022.03.002